HSP90B2P and Behcet disease: On the other hand, the therapeutic approaches involving HSP immunomodulation may be available as “oral toleration” using the peptide of HSP (336–351) linked to recombinant cholera toxin B for BD patients with advanced uveitis, as demonstrated by Stanford et al. [60].